JP2016534715A5 - - Google Patents

Download PDF

Info

Publication number
JP2016534715A5
JP2016534715A5 JP2016524143A JP2016524143A JP2016534715A5 JP 2016534715 A5 JP2016534715 A5 JP 2016534715A5 JP 2016524143 A JP2016524143 A JP 2016524143A JP 2016524143 A JP2016524143 A JP 2016524143A JP 2016534715 A5 JP2016534715 A5 JP 2016534715A5
Authority
JP
Japan
Prior art keywords
subject
polymorphisms
gabra2
schizophrenia
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016524143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534715A (ja
JP6524073B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2014/051000 external-priority patent/WO2015054792A1/en
Publication of JP2016534715A publication Critical patent/JP2016534715A/ja
Publication of JP2016534715A5 publication Critical patent/JP2016534715A5/ja
Application granted granted Critical
Publication of JP6524073B2 publication Critical patent/JP6524073B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016524143A 2013-10-17 2014-10-17 抗精神病薬誘導体重増加に関連する遺伝子マーカーおよびその使用のための方法 Expired - Fee Related JP6524073B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892094P 2013-10-17 2013-10-17
US61/892,094 2013-10-17
PCT/CA2014/051000 WO2015054792A1 (en) 2013-10-17 2014-10-17 Genetic markers for antipsychotic induced weight gain and methods for use thereof

Publications (3)

Publication Number Publication Date
JP2016534715A JP2016534715A (ja) 2016-11-10
JP2016534715A5 true JP2016534715A5 (https=) 2017-11-24
JP6524073B2 JP6524073B2 (ja) 2019-06-05

Family

ID=52827506

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016524143A Expired - Fee Related JP6524073B2 (ja) 2013-10-17 2014-10-17 抗精神病薬誘導体重増加に関連する遺伝子マーカーおよびその使用のための方法

Country Status (12)

Country Link
US (1) US10301678B2 (https=)
EP (2) EP3058106B1 (https=)
JP (1) JP6524073B2 (https=)
KR (1) KR102252926B1 (https=)
CN (1) CN106029901A (https=)
AU (1) AU2014336928B2 (https=)
CA (1) CA2943951C (https=)
ES (1) ES2728072T3 (https=)
IL (1) IL245159B (https=)
PT (1) PT3058106T (https=)
SG (1) SG11201602998QA (https=)
WO (1) WO2015054792A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210033619A1 (en) * 2018-02-09 2021-02-04 Metabolomic Diagnostics Limited Methods of predicting pre term birth from preeclampsia using metabolic and protein biomarkers
CN110317868B (zh) * 2019-08-09 2020-05-19 新疆医科大学第二附属医院 一种基于多基因组合交互作用预测二代抗精神病药物治疗精神分裂症致体重增加分析方法
CN117547526A (zh) * 2023-10-24 2024-02-13 首都医科大学附属北京朝阳医院 γ-氨基丁酸GABA在制备防治奥氮平诱发的不良反应药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
JP4071277B2 (ja) 1993-11-12 2008-04-02 ピーエイチアールアイ・プロパティーズ・インコーポレーテッド 核酸検出用ハイブリダイゼーションプローブ、共通ステム、方法およびキット
US20030104453A1 (en) 2001-11-06 2003-06-05 David Pickar System for pharmacogenetics of adverse drug events
US8012718B2 (en) 2006-03-31 2011-09-06 Genomas, Inc. Physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs
US20070292962A1 (en) * 2006-04-10 2007-12-20 Duke University Methods and compositions for genetic markers for autism
US7795033B2 (en) 2007-03-19 2010-09-14 The United States Of America As Represented By The Department Of Health And Human Services Methods to predict the outcome of treatment with antidepressant medication
US8476012B2 (en) 2008-04-18 2013-07-02 Genomas, Inc. Physiogenomic method for predicting metabolic and cardiovascular side effects of thiazolidinediones
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
JP2015501652A (ja) 2011-12-14 2015-01-19 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Gabr−a2診断

Similar Documents

Publication Publication Date Title
CN102177436B (zh) 鉴定疾病风险因子的方法
Wang et al. Mutations in SPATA7 cause Leber congenital amaurosis and juvenile retinitis pigmentosa
Phusantisampan et al. Association of genetic polymorphisms in the RET-protooncogene and NRG1 with Hirschsprung disease in Thai patients
JP2018038436A5 (https=)
JP2014530819A5 (https=)
JP2018518147A5 (https=)
JP5608944B2 (ja) 高血圧感受性遺伝子群の同定
JP2013507127A5 (https=)
De Silva et al. Genotyping of the Duffy blood group among Plasmodium knowlesi-infected patients in Malaysia
JP2016534715A5 (https=)
JP2017503493A5 (https=)
Chen et al. Chimerin 2 genetic polymorphisms are associated with non-proliferative diabetic retinopathy in Taiwanese type 2 diabetic patients
CN105018602B (zh) 抗精神病药物相关代谢综合征的易感基因及其应用
Song et al. The influence of MRAS gene variants on ischemic stroke and serum lipid levels in Chinese Han population
Manage et al. Genotyping single nucleotide polymorphisms in human genomic DNA with an automated and self-contained PCR cassette
Kim et al. Association between cytochrome P450 promoter polymorphisms and ischemic stroke
CN106591484B (zh) 一种基于hsp90b1基因多态性位点基因型预测糖皮质激素治疗sle疗效的用途和试剂盒
JP6470044B2 (ja) がんに対する免疫療法の有効性の予測方法
CN104789673B (zh) rs1800818在检测新布尼亚病毒引起的发热伴血小板减少综合征中的应用
Al-Shehmany et al. Genetic association between interleukin IL-18-137G/C and IL-18-607 C/A polymorphisms and type 1 diabetes in Egyptian population
Vishwakarma et al. Association of CD14 and macrophage migration inhibitory factor gene polymorphisms with inflammatory microRNAs expression levels in ankylosing spondylitis and polyarthralgia
CN104946738B (zh) 内脏脂肪蓄积易感性的判定方法
CN107034288A (zh) 一种基于Trap1基因多态性位点基因型预测糖皮质激素治疗SLE疗效的用途和试剂盒
Gupta et al. Pleckstrin-Homology-Domain-Containing Protein (PLEKHA1) gene and their association with age related macular degeneration (AMD) in Indian patients
WO2015168252A1 (en) Mitochondrial dna copy number as a predictor of frailty, cardiovascular disease, diabetes, and all-cause mortality